Clinical trial · Observational
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
NCT03123263CI-TRIAL-00040455completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study retrospectively looks at changes in Echocardiographic parameters while using transtuzumab
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- LVEF
- timeFrame
- Baseline (prior to therapy), at 3-6 months (mid-therapy), and at 1 year (end of therapy)
- description
- LV ejection fraction
Secondary outcomes (1)
- measure
- Number of Participants Hospitalized for Cardiac Issues.
- timeFrame
- 1 year
- description
- any hospitalization for cardiac issues
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Stage 1,2,3 breast cancer * Her2+ Exclusion Criteria: * Stage 4 cancer
References
Publications (0)
Data not yet available
No reference posted for this study.